INVESTORS
NEWSROOM
Responsibility
SUBSCRIBE
CONSUMERS
HEALTHCARE PROFESSIONALS
CAREERS
ABOUT ABBOTT
Abbott Reports Q1 Earnings
Abbott's diverse portfolio continues fueling growth and life-changing innovation in a challenging time.
There was nothing ordinary about the first quarter of 2020 as the coronavirus pandemic spurred shelter-in-place orders globally, nearly halted non-essential travel and tested healthcare systems worldwide.
Despite this unprecedented time, Abbott remains resilient with its diversified business model.
For the quarter, our worldwide sales of $7.7 billion increased 4.3% on an organic basis (2.5% reported), led by a strong performance in Diabetes Care, Nutrition, Established Pharmaceuticals, and Molecular and Rapid Diagnostics.
Our life-changing technologies, innovative pipeline and focused execution continue to drive growth and shareholder value.
Here are some key highlights:
For full financials, you can read our press release, or take a look at some additional materials below:
Abbott President and CEO Robert Ford shared his views on first-quarter performance:
Download a summary of Abbott’s earnings highlights here.
For more information on Abbott’s earnings results, see the news release.